© 1997 American Heart Association, Inc.
Articles |
Dose-Dependent Suppression of Transplant Arteriosclerosis in Aorta-Allografted, Cholesterol-Clamped Rabbits
Suppression Not Eliminated by the Cholesterol-Raising Effect of Cyclosporine
From the Departments of Thoracic Surgery (H.O.A.) and Clinical Biochemistry (H.O.A., P.H.), Rigshospitalet, Hellerup; the Clinical Institute, University of Odense (S.S.), Odense; the Department of Pathology, Hvidovre Hospital (B.F.H.), Hvidovre; and the Department of Clinical Biochemistry, Herlev Hospital (B.G.N.), Herlev, Denmark.
Abstract Cyclosporine may suppress transplant arteriosclerosis; however, it also raises plasma cholesterol, which could promote the disease. Our aim was to test these hypotheses experimentally. In experiment 1 (n=34), cholesterol was clamped at a human level of 5 to 7 mmol/L, and rabbits were given either saline or cyclosporine in a low, medium, or high dose. In experiment 2 (n=15), in which dietary cholesterol was fixed at 0.05 g·kg-1·d-1, and experiment 3 (n=16), in which no dietary cholesterol was added to the chow, rabbits were given either medium-dose cyclosporine, saline, or vehicle. The duration of each experiment was 5 weeks. In experiment 1, cyclosporine attenuated the development of transplant arteriosclerosis dose dependently (trend test: P<.0001). Cyclosporine also suppressed, in a dose-dependent manner, the activation of the immune system (trend test: P<.05) and the presence of T lymphocytes (trend test: P<.0001) and macrophages in the intima (trend test: P<.01). Despite a higher plasma cholesterol level in cyclosporine-treated rabbits compared with saline-treated rabbits in both experiment 2 (4.9 versus 2.9 mmol/L) and experiment 3 (1.6 versus 0.8 mmol/L), transplant arteriosclerosis was significantly reduced by cyclosporine (Mann-Whitney U test: P<.05 and P<.05). These results suggest that cyclosporine suppresses experimental transplant arteriosclerosis dose dependently. Accordingly, in the assessment of the optimal cyclosporine dose to heart-transplanted patients, it should be taken into account that a dose reduction may promote transplant arteriosclerosis.
Key Words: transplantation • arteriosclerosis • rabbits • cyclosporine • cholesterol •
This article has been cited by other articles:
 |
|
 |
|
  V. Fuster, P. R. Moreno, Z. A. Fayad, R. Corti, and J. J. Badimon Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts J. Am. Coll. Cardiol., September 20, 2005; 46(6): 937 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Religa, K. Bojakowski, M. Bojakowska, Z. Gaciong, J. Thyberg, and U. Hedin Allogenic immune response promotes the accumulation of host-derived smooth muscle cells in transplant arteriosclerosis Cardiovasc Res, February 1, 2005; 65(2): 535 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nilsson, G. K. Hansson, and P. K. Shah Immunomodulation of Atherosclerosis: Implications for Vaccine Development Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 18 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Murakami, F. Kambe, H. Mitsuyama, K. Okumura, T. Murohara, S. Niwata, R. Yamamoto, and H. Seo Cyclosporin A Enhances Interleukin-8 Expression by Inducing Activator Protein-1 in Human Aortic Smooth Muscle Cells Arterioscler Thromb Vasc Biol, November 1, 2003; 23(11): 2034 - 2040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Schroepfer Jr. Oxysterols: Modulators of Cholesterol Metabolism and Other Processes Physiol Rev, January 1, 2000; 80(1): 361 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. O. Andersen, B. F. Hansen, P. Holm, S. Stender, and B. G. Nordestgaard Effect of Cyclosporine on Arterial Balloon Injury Lesions in Cholesterol-Clamped Rabbits : T Lymphocyte–Mediated Immune Responses Not Involved in Balloon Injury–Induced Neointimal Proliferation Arterioscler Thromb Vasc Biol, July 1, 1999; 19(7): 1687 - 1694. [Abstract] [Full Text] [PDF]
|
|